RCS - Retroscreen Vlgy Grp - hVIVO HCM of AL-8176 in RSV for Alios BioPharma <Origin Href="QuoteRef">RVG.L</Origin>

hVIVOAnnouncement

06/09/2014 20:42

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140728:nRSb4431Na


RNS Number : 4431N
Retroscreen Virology Group PLC
28 July 2014 
 
For immediate release 07.00: 28 July 2014 
 
RETROSCREEN VIROLOGY GROUP PLC 
 
("Retroscreen" or the "Company") 
 
RETROSCREEN CONDUCTSLANDMARK hVIVO HUMAN CHALLENGE MODEL STUDY OF AL-8176 IN
RSV FOR ALIOS BIOPHARMA 
 
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO Human
Challenge Models ("HCMs") of disease, acknowledges the announcement by Alios
BioPharma Inc. of positive results from a landmark human viral challenge study
of its oral anti-RSV nucleoside analog AL-8176 in Respiratory Syncytial Virus
("RSV") infection that was conducted by Retroscreen.  This study is considered
to be a major endorsement of the clinical utility of Retroscreen's hVIVO
platform, in rapidly establishing proof of concept and dose-ranging for
investigational new drugs early on in their development lifecycle. 
 
The study was a randomized, double-blind, placebo-controlled Phase 2 challenge
study of AL-8176 in healthy adult volunteers, who were infected intranasally
with RSV.  AL-8176 achieved its primary and secondary endpoints of reduction
in viral load (p<0.0002), and improvement in symptom scores (p<0.02), as
compared to placebo.  AL-8176 was well tolerated, with no discontinuations of
study drug and no clinically significant laboratory abnormalities. 
 
This viral HCM study was conducted by Retroscreen at its purpose built,
state-of-the-art clinical quarantine unit in London, UK.  It utilised an
adaptive design and enrolled a total of 62 subjects across 3 quarantine
periods.  The study started in January 2014 and was conducted by Retroscreen
in a little under 6 months. 
 
Kym Denny, Chief Executive Officer, commented, "This study of Alios' AL-8176
product for RSV infection, conducted by Retroscreen in just under 6 months,
highlights hVIVO's ability to surpass field-based studies in producing clean
compelling data in an accelerated timeframe, through targeted subject
recruitment and defined timing of infection.  The ability to accelerate the
development of new drugs underpins our expansion into new HCMs, including for
respiratory diseases such asthma and Chronic Obstructive Pulmonary Disease
(COPD)". 
 
For further information please contact: 
 
Retroscreen Virology Group plc                                                
        +44 207 756 1300 
 
Kym Denny (CEO) 
 
Graham Yeatman (FD) 
 
Numis Securities Limited                                                      
            +44 207 260 1000 
 
Michael Meade / Freddie Barnfield (Nominated Adviser) 
 
James Black / Michael Burke (Corporate Broking) 
 
Notes to Editors: 
 
About Retroscreen 
 
Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life
sciences company pioneering a technology platform called hVIVO which uses
human models of disease involving healthy volunteers to study new drugs and
investigate disease in a safe, controlled environment. 
 
Retroscreen has established itself as the world leader in this field through
the provision of clinical services to third party study sponsors.  To date,
the Company has conducted over 35 clinical studies, involving more than 1700
volunteers for a range of leading industry, governmental and academic
clients. 
 
However, Retroscreen's hVIVO platform has a much wider application in helping
to understand illness better because the Company believes that the best way to
understand human disease is by studying it in humans, not laboratory models. 
 
About Alios BioPharma 
 
Alios BioPharma is a clinical stage biopharmaceutical company in South San
Francisco, CA that is developing novel antiviral therapies for the treatment
of respiratory diseases.  The Alios virology discovery and development
platform consists of a proprietary chemical library of nucleoside analogs as
well as novel, proprietary virology-based screening systems.  Alios is
developing a portfolio of potential therapeutics for viral infections
including respiratory syncytial virus (RSV), influenza, rhinovirus and
coronavirus. 
 
For more information please visit www.aliosbiopharma.com. 
 
This information is provided by RNS
The company news service from the London Stock Exchange